PPT-CROI 2019 Scientific summary of the major clinical studies presented at CROI 2019

Résumé scientifique des principales études cliniques présentées à la CROI 2019 CAHR is pleased to provide this scientific summary of the major clinical studies presented at the Conference on Retroviruses and Opportunistic Infections CROI 2019 The synthesis aims to improve the cascade of care by increasing the skills and knowledge of Canadian health care professionals working in the realm of HIV This presentation was made possible with the support of an educational grant from ViiV Healthcare. Nina Kim, MD . Associate Professor of Medicine. Division of Allergy & Infectious Diseases. University of Washington. No financial conflicts of interest. ION-4. Ledipasvir-Sofosbuvir. for 12 weeks. New Drugs in Development Are We Ready for Long-Acting ART? Melanie A. Thompson, MD AIDS Research Consortium of Atlanta Follow me on Twitter @ drmt Financial Relationships With Commercial Entities Dr Thompson's institution has received grants for research from Bristol-Myers Squibb, CytoDyn, Inc, Frontier Biotechnologies, Gilead Sciences, Inc, GlaxoSmithKline, 1 Queen Mary University, London, United Kingdom; 2 EPIMED GmbH, Berlin, Germany; 3 Hospital Universitario Fundación Jiménez Díaz , Madrid, Spain; 4 Central Institute of Epidemiology, Moscow, Russian Federation; Joseph J. Eron, Jr, MD. Professor of Medicine. University of North Carolina. Chapel Hill, North Carolina. Financial Relationships With Commercial Entities. Dr Eron has served as an ad hoc consultant to Janssen, ViiV Healthcare, Merck, and Gilead Sciences, Inc. His institution receives contracts for clinical research on which Dr Eron is the local principal investigator from Janssen Therapeutics, ViiV Healthcare, and Gilead Sciences, Inc. AND OPPORTUNISTIC INFECTIONS. CROI 2023. 19-23 FEBRUARY 2023. Faculty. Pedro . Cahn. , Buenos-Aires, Argentina. Anton . Pozniak. , London, UK. François . Raffi. , Nantes, France. Long Acting Therapies. Résumé scientifique des principales études cliniques présentées à . le 28e . Congrès. . annuel. . canadien. de recherche sur le VIH/. sida. CAHR is pleased to provide this scientific summary of the major clinical studies presented at the 28th Annual Canadian Conference on HIV/AIDS Research (CAHR 2019). The synthesis aims to improve the cascade of care by increasing the skills and knowledge of Canadian health care professionals working in the realm of HIV. This presentation was made possible with the support of an educational grant from ViiV Healthcare.. Prediction. . of . events. . after. ART. initiation. INSTI . and IRIS ?. Test and . Treat. Same. Day. Switch DTG/ABC/3TC. to BIC/F/TAF. Miscellaneous. ART. Test and Treat the Same Day - Is this feasible ?. Shireesha Dhanireddy. Robert Harrington. March 17, 2014. No financial conflicts of interest. Outline. Treatment Studies. Tenofovir. . alafenamide. (TAF) in a single-tablet regimen in initial HIV-1 infection . by Baseline NRTI Resistance . and Second-Line NRTI Use. Dannae. Brown,. 1. . Ruolan. Wang,. 2. Mark Underwood,. 2. Judy Hopking,. 3. Maria Claudia Nascimento,. 4. . Michael Aboud,. 4. . Jörg. Résumé scientifique des principales études cliniques présentées à . le 10e . Congrès. de . l’IAS. sur les sciences du VIH. CAHR is pleased to provide this scientific summary of the major clinical studies presented at the 10th IAS Conference on HIV Science). The synthesis aims to improve the cascade of care by increasing the skills and knowledge of Canadian health care professionals working in the realm of HIV. This presentation was made possible with the support of an educational grant from ViiV Healthcare.. Judith S. Currier, MD, MSc. Professor of Medicine. University of California Los Angeles. Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:. Jeffrey Lennox, MD. Professor of Medicine. Emory University. Atlanta. , Georgia. Financial Relationships With Ineligible Companies (Formerly Described as Commercial Interests by the ACCME) Within the Last 2 Years:. Alafenamide. in Renal Impairment. A Pozniak. 1. , J Arribas. 2. , . SK Gupta. 3. , . FA Post. 4. , A Avihingsanon. 5. , . G Crofoot. 6. , . K Lichtenstein. 7. , M Ramgopal. 8. , P Chetchotisakd. 9. , MW Fordyce. AND OPPORTUNISTIC INFECTIONS. (CROI 2020). BOSTON| 8-11 MARCH 2020. Faculty. Pedro . Cahn. , Buenos-Aires, Argentina. Anton . Pozniak. , London, UK. François . Raffi. , Nantes, France. This presentation is made in complete editorial freedom .